Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2025 04:08 ET | Source: Research and Markets

Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances

Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The atopic dermatitis market...
July 21, 2025 04:49 ET | Source: Research and Markets

Dermatology Collaboration and Licensing Agreements Trends Report 2025 with Directory of 474 Deals Since 2016 - Company A-Z, Therapy Focus, Upfront, Milestone, Royalties

Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the...
July 16, 2025 08:00 ET | Source: ViaDerma, Inc.

ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes

LOS ANGELES, July 16, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, announced today that its 2024 Annual Report has been posted to the...
June 04, 2025 08:30 ET | Source: ViaDerma, Inc.

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working...
May 19, 2025 10:34 ET | Source: Research and Markets

Atopic Dermatitis (Atopic Eczema) Global Clinical Trials Review 2025 | Now Available

Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. The report delivers a...
April 22, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June...
April 08, 2025 09:00 ET | Source: Codex Labs Corporation

Codex Labs OTC Bia Eczema Relief Lotion Is Awarded Seal of Acceptance from National Eczema Association and Microbiome-Friendly Certification from MyMicrobiome

San Jose, CA, USA, April 08, 2025 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley skintech company, announced that its over-the-counter (OTC) Bia Eczema Relief Lotion has been awarded the Seal of...
February 26, 2025 10:00 ET | Source: Derm-Biome Pharmaceuticals, Inc

Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...
December 10, 2024 08:00 ET | Source: ViaDerma, Inc.

ViaDerma Announces Significant 2024 Achievements and International Expansion

LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, proudly announces the completion of a...
November 11, 2024 04:47 ET | Source: Research and Markets

Dermatology Collaboration and Licensing Agreements Analysis Report 2024: Detailed Review and Access to Contract Documents - Upfront, Milestone, Royalties, Company A-Z, Therapy and Technology

Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...

Next Page keyboard_arrow_right